Prosecution Insights
Last updated: November 20, 2026
Application No. 18/554,944

MICROBUBBLE-ASSISTED ULTRASOUND-GUIDED THERAPY

Non-Final OA §102§103§112
Filed
Oct 11, 2023
Priority
Apr 12, 2021 — provisional 63/173,956 +2 more
Examiner
VU, JAKE MINH
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Board of Regents of the University of Texas System
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
333 granted / 809 resolved
-18.8% vs TC avg
Strong +27% interview lift
Without
With
+26.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
50 currently pending
Career history
855
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
41.3%
+1.3% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
22.4%
-17.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 809 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of Applicant’s Restriction Requirement Response and Amendment filed on 08/31/2026; and IDS filed on 09/05/2025 and 10/11/2023. Claims 57-58, 61-62, 64 have been canceled. Claims 1-2, 4-5, 10, 13, 17, 22, 25, 27, 30, 32, 36, 40, 44 are pending in the instant application. Claims 25, 27, 30, 36, 40, 44 are withdrawn from consideration. Election/Restrictions Applicant’s election without traverse of Group I (claims 1-2, 4-5, 10, 13, 17, 22, 25, 27, 30, 32) and specie elections of “about 1um to 10um” (claim 22) and “decorated with spermine-dextran conjugates” (claim 17) in the reply filed on 08/31/2026) is acknowledged. Note, claims 10, 25, 27 and 30 are drawn to non-elected species. Note, the following rejection is based upon art which was found incidental to the search for the elected species. This is not indicative that the entire scope of the claims has been examined; however, the following art is being applied in an effort to promote compact prosecution of the case. Thus, claim 10 is rejoined. Claim Rejections - 35 USC § 112, 2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 22 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 22 recites the broad recitation “about 1um and about 10um”, and the claim also recites “about 1um and 5um, or is about 3um” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note, withdrawn claim 27 also has this 112 issue. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 4-5, 10, 13, 17, 22, 32 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by HEALEY et al (US 2016/0243234). Regarding claim 1 and 4, HEALEY teaches a method of ultrasound mediated delivery of drugs (see title and abstract) comprised of: administering microbubbles with drug, such as gene, to the targeted tissue (see abstract; [0005]; [0008]), which reads on administering to one or more target cells a composition comprising microbubbles loaded with a payload; and application of ultrasound after trapping facilitates extravasation of the drug to the targeted tissue (see [0080]), wherein extravasation is sonoporation (see [0005]) and reads on administering an ultrasound stimulus to the one or more target cells, wherein the ultrasound stimulus is effective to sonoporate the one or more target cells. Regarding claim 5, HEALEY teaches cancer cells (see [0111]). Regarding claim 10, HEALEY teaches microbubbles with ligands attached for targeting to cell surface receptors (see [0007]; [0012]), which reads on the microbubbles comprise targeting molecules on the external surfaces of the microbubbles, the targeting molecules being effective to bind the one or more target cells. Regarding claim 13, HEALEY teaches ultrasound scanner with a 2 MHz probe for 45 seconds (see [0319]), which reads on the ultrasound stimulus is administered for between at least about 30-120 seconds. Regarding claim 17, HEALEY teaches gas microbubbles may consist of, for example but not limited to, a low solubility perfluorocarbon gas core stabilised with a negatively charged phospholipid membrane, which reads on the microbubbles comprise shells comprising phospholipids. Regarding claim 22, HEALEY teaches 1 to 10 um (see claim 1). Regarding claim 32, HEALEY teaches in order to study activation of the microbubbles, an in-vitro system has been developed (see [0187]). Claim(s) 1-2, 4-5, 13, 17, 22, 32 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by MIAO et al (US 2021/0370037). Regarding claims 1 and 4, MIAO teaches a method of ultrasound mediated delivery of gene and drug (see title and abstract) comprised of: delivering microbubbles and therapeutic compounds, such as gene, to targeted tissue sites ([0010]), wherein the bioactive agent is conjugated to the microbubbles (see [0081]), which reads on administering to one or more target cells a composition comprising microbubbles loaded with a payload; and using ultrasound (see [0010]) for sonoporation (see [0151]), which reads on administering an ultrasound stimulus to the one or more target cells, wherein the ultrasound stimulus is effective to sonoporate the one or more target cells. Regarding claim 2, MIAO teaches the therapeutic agents, such as siRNA and mRNA (see [0089]). Regarding claim 5, MIAO teaches tumor sites (see [0108]). Regarding claim 13, MIAO teaches sonication is performed for a period of between about 10 seconds and about 15 minutes (see claim 11). Thus, it would have been obvious to optimize within this time range. Regarding claim 17, MIAO teaches phospholipids (see [0162]), such as DSPC (see [0123]). Regarding claim 22, MIAO teaches average size of 1.5 um (see [0249]). Regarding claim 32, MIAO teaches a reference for ultrasound parameters in in-vitro experiments tested in HEKsp3T cells (see [0139]), which reads on in vitro method. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-2, 4-5, 13, 17, 22, 32 is/are rejected under 35 U.S.C. 103 as being unpatentable over MIAO et al (US 2021/0370037) in view of AZZAM et al (Dextran-spermine conjugate: an efficient vector for gene delivery. Macromol. Symp., 195: 247-262. (2003)). As discussed above, MIAO teaches Applicant’s invention. Regarding claim 17, MIAO does not teach Applicant’s elected specie of “decorated with spermine-dextran conjugates”. AZZAM teaches the prior art had known of using dextran-spermine conjugate for efficient gene delivery (see title and abstract). It would have been obvious to the person of ordinary skill in the art at the time the invention was made to incorporate “decorated with spermine-dextran conjugates”. The person of ordinary skill in the art would have been motivated to make those modifications, because it would increase the efficiency of gene delivery, and reasonably would have expected success because both references dealt with gene delivery. Telephonic Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAKE MINH VU whose telephone number is (571)272-8148. The examiner can normally be reached Mon-Fri 9:00am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAKE M VU/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Oct 11, 2023
Application Filed
Nov 12, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12796711
METHODS TO INCREASE MILK YIELD AND YIELD OF MILK CONSTITUENTS IN LACTATING RUMINANTS
5y 10m to grant Granted Nov 17, 2026
Patent 12779060
RADIOACTIVE ISOTOPE-LABELED, PHOTO-CROSSLINKABLE HYDROGEL, AND PREPARATION METHOD THEREFOR
5y 3m to grant Granted Nov 03, 2026
Patent 12779057
HEPARANASE COMPOUNDS AND METHODS OF USE
5y 0m to grant Granted Nov 03, 2026
Patent 12773389
PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA
1y 2m to grant Granted Oct 27, 2026
Patent 12765561
PEST CONTROL COMPOSITION
3y 10m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
68%
With Interview (+26.7%)
4y 2m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 809 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month